Overview

• Williams says she began a GLP‑1 regimen in April and has lost roughly 13–14 kilograms, with the drug identified in reporting as Ozempic and no side effects reported to date.
• She describes the choice as health‑driven, citing a family history of diabetes plus ongoing knee issues following childbirth.
• She has partnered with telehealth provider Ro as a patient‑ambassador for a new multi‑year campaign to normalize medical use of GLP‑1 therapies.
• Ro’s campaign shows Williams using the app and administering injections, with planned placements across digital, TV, outdoor sites, the US Open, Times Square, and New York City subways.
• Coverage notes GLP‑1 drugs were developed for type 2 diabetes, have FDA‑cleared uses for some patients, can cause gastrointestinal side effects, often require continued use, and rising demand has strained supply for diabetic patients.